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Cyclin A triggers Mitosis either via the Greatwall
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Abstract
Two mitotic cyclin types, cyclin A and B, exist in higher eukary-
otes, but their specialised functions in mitosis are incompletely
understood. Using degron tags for rapid inducible protein
removal, we analyse how acute depletion of these proteins
affects mitosis. Loss of cyclin A in G2-phase prevents mitotic
entry. Cells lacking cyclin B can enter mitosis and phosphorylate
most mitotic proteins, because of parallel PP2A:B55 phosphatase
inactivation by Greatwall kinase. The final barrier to mitotic
establishment corresponds to nuclear envelope breakdown, which
requires a decisive shift in the balance of cyclin-dependent kinase
Cdk1 and PP2A:B55 activity. Beyond this point, cyclin B/Cdk1 is
essential for phosphorylation of a distinct subset of mitotic Cdk1
substrates that are essential to complete cell division. Our results
identify how cyclin A, cyclin B and Greatwall kinase coordinate
mitotic progression by increasing levels of Cdk1-dependent
substrate phosphorylation.
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Introduction
Cdk1 phosphorylates over 1,000 proteins (Daub et al, 2008;
Dephoure et al, 2008) within the brief 20–30 min window of mitotic
entry. Rising levels of Cdk1 activity correlate with centrosome sepa-
ration and chromosome condensation in prophase, followed by
nuclear envelope breakdown (NEBD) and mitotic spindle formation
in prometaphase, and the alignment of bi-oriented sister chromatids
at the metaphase plate (Gavet & Pines, 2010). Binding of a cyclin
partner is critical for allosteric activation of Cdks. Two families of
mitotic cyclins, termed A and B, work with Cdk1 to orchestrate
mitotic entry in higher eukaryotes (Fung & Poon, 2005; Hochegger
et al. 2008). Despite the central importance of these proteins for cell
cycle control, the functional specialisation of mammalian A- and B-
type cyclins remains unclear. Following the depletion of maternal
pools of early embryonic cyclins A1 and B3, somatic mammalian
cells express one A-type cyclin, A2, and two B-type cyclins, B1 and
B2. Specific binding partners for cyclin A2 and B1 have been identi-
fied (Pagliuca et al, 2011), but the precise contributions of these
two cyclins to mitotic entry remain unclear.
Genetic depletion in mice suggests an essential role for cyclin A2
for early development, but not for embryonic fibroblast and liver cell
proliferation (Kalaszczynska et al, 2009; Gopinathan et al, 2014).
Antibody injections against cyclin A2 or depletion of human cyclin
A2 by siRNA delay mitotic entry, and this is further enhanced by co-
depletion of cyclin B1 (Furuno et al, 1999; Fung et al, 2007; Gong
et al, 2007; Gong & Ferrell, 2010). A mechanism involving Plk1 acti-
vation has been suggested (Gheghiani et al, 2017; Vigneron et al,
2018), although an essential role of Plk1 in the G2/M transition
remains contentious (Burkard et al, 2007). Likewise, work in
mammalian cell extracts documented how cyclin A synergises with
cyclin B to control the mitotic entry threshold at the level for Cdk1
activation (Deibler & Kirschner, 2010). A confounding factor in the
genetic analysis of cyclin A2 has been its dual role in S phase and
mitosis (Katsuno et al, 2009; Chibazakura et al, 2011), making it dif-
ficult to directly investigate G2-specific defects. Furthermore, mitotic-
specific functions of cyclin A2 in modulating Plk1 activity have also
been reported (Kabeche & Compton, 2013; Dumitru et al, 2017).
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Murine cyclin B1 is essential for development (Brandeis et al,
1998) and critical for mitotic entry in early mouse embryos (Strauss
et al, 2018). Conversely, mice lacking cyclin B2 live healthily, with-
out apparent defects (Brandeis et al, 1998). These results stand in
stark contrast to observations from experiments involving siRNA
depletion of B-type cyclins in human somatic cell lines that show
surprisingly mild mitotic entry defects (Chen et al, 2008; Gong &
Ferrell, 2010; Soni et al, 2014). The observed unperturbed G2/M
transition in cyclin B-depleted human cells could be explained by a
synergy between A- and B-type cyclins in mitotic entry (Gong &
Ferrell, 2010). Cyclin B could also be critical to elevate Cdk1 activity
after mitotic entry (Lindqvist et al, 2007) and compensate for the
premature loss of cyclin A (Geley et al, 2001; Voets et al, 2015).
Specific localisation of cyclin B in mitosis may also contribute to its
specialised functions, as was recently shown in connection with
Mps1 activation and spindle assembly checkpoint (SAC) signalling
(Alfonso-Pe´rez et al, 2019; Hayward et al, 2019).
In parallel to mitotic cyclin/Cdk1 activation, the inactivation of
the Cdk1 counteracting phosphatase PP2A:B55 by Greatwall
kinase (GWL) via its substrates ENSA and ARPP19 also plays a
critical role in mitotic entry in Xenopus egg extracts (Castilho
et al, 2009; Gharbi-Ayachi et al, 2010; Mochida et al, 2010).
However, human and mouse cells lacking Greatwall kinase read-
ily enter mitosis (Burgess et al, 2010; Alvarez-Ferna´ndez et al,
2013), but fail to undergo accurate sister-chromatid segregation
and cell division (Cundell et al, 2016). Thus, it appears that
human cells can enter mitosis in the absence of cyclin B or Great-
wall, but it remains unclear to what extent the kinase activation
and phosphatase inactivation pathways compensate for each
other. Moreover, the precise G2-specific role of cyclin A in this
regulatory network is still an open question. In this study, we
have taken a genetic approach based on optimised degron tagging
to address these questions.
Results
A double degron of mAID and SMASh allows efficient depletion of
cyclin A and B in RPE-1 cells
Rapid, precise and uniform depletion is critical to investigate the
functions of mitotic cyclins within a single cell cycle. We have
recently reported that a combination of mAID- (Natsume et al,
2016) and SMASh- (Chung et al, 2015) tags results in highly effi-
cient induced degradation (Lemmens et al, 2018), and applied this
strategy (see Fig 1A) to comprehensively analyse the functions of
cyclin A2 and B1 in a non-transformed, h-TERT immortalised
human epithelial cell line, RPE-1. Firstly, we designed gene targeting
constructs and gRNA/Cas9 constructs to inducibly express OsTIR1
from the human Rosa26 locus (Fig 1B, upper panel). This was criti-
cal to achieve a controllable and uniform degradation of mAID-
tagged proteins. Next, we introduced the mAID-SMASh double tag
in the C terminus of the human CCNA2 and CCNB1 genes using
targeting vectors and gRNA/Cas9 cleavage (See Fig 1B middle and
bottom panel and Materials and Methods). Targeted clones were
selected using a T2A coupled gene conferring resistance to
Neomycin. Gene targeting was confirmed by genomic PCR (Fig 1C).
Both cyclins were essentially undetectable by immunoblotting after
2–4 h of both mAID- and SMASh-induced degradation (Fig 1D)
using the “DIA” cocktail (Doxycycline/IAA for mAID and Asv for
SMASh, see Materials and Methods section). Quantification of this
depletion experiment (Fig 1E) shows 50% depletion within the first
hour and an ultimate depletion to < 5% of control protein levels
within 2–4 h. Activation of both degradation systems was highly
effective to trigger rapid degradation of either cyclin compared to
the individual degron systems. We observed a strong synergy in the
combined degron compared to inducing the individual degradation
systems (Fig 1F). Further analysis confirmed that depletion of cyclin
▸Figure 1. Generation and characterisation of cell lines expressing mAID-SMASh-tagged cyclin A2 or B1.A Schematic of protein degradation using AID and SMASh systems. The SMASh tag consists of the self-cleaving viral HCV NS3 protease fused in cis to a constitutive
destabilising peptide. The tag detaches itself from the target protein in the off condition. Upon inhibition by the protease inhibitor, asunaprevir (Asv), the tag
remains on the target protein and exposes it to the cellular degradation machinery, while the old protein is depleted depending on its specific half-life. The AID-tag
relies on the expression of the plant F-box protein TIR1 that combines with mammalian Skp1 and Cul1 to form a functional SCF E3 ligase that is activated to
ubiquitylate the AID degron tag upon stimulation by the hormone Auxin (IAA). In the case of the double tag combination, newly synthesised proteins are depleted
by the two independent degradation systems. Old proteins are destabilised by the mAID-tag (mini-AID).
B Knock-in strategy for inducible OsTIR1 expression at the human Rosa26 locus and endogenous cyclin A2 and B1 protein tagging. We integrated mAID-SMASh-T2A-
neomycin in-frame at the C terminus of the coding sequence of cyclins A2 and B1. The chosen length for the homologous regions for gene targeting was ~ 1 kb.
C To verify gene targeting primers were designed in the genomic locus and in the cassette (indicated in (B)) and used to amplify genomic DNA from different cell
lines: wild-type RPE-1, RPE-1 expressing OsTIR1, CycA2dd, CycB1dd and primers amplifying a region of the Kif23 gene were used as a positive control (see Material
and Methods section for primer sequences).
D, E (D) Representative immunoblots and (E) quantitation showing timecourse of induced degradation of double degron-tagged cyclin A and cyclin B (A2dd, B1dd). *
indicates cross-reacting band. (n = 3 experiments, s.d. indicated by error bars). Doxycycline/IAA/Asv (DIA, see Material and Methods) was added to asynchronous
cells for indicated time before extract preparation and immunoblotting.
F Comparison of protein degradation efficiency using different degrons. Cells were incubated for indicated time periods with Asv or DOX/IAA or both (DIA, see
Material and Methods) then collected for Western blot analysis. Doxycycline was added 2 h before addition of IAA or Asv/IAA. To determine protein degradation,
either cyclin A2 or cyclin B1 was probed as indicated. Anti-myc antibody was used to check OsTIR1-myc expression. Asterisks indicate non-specific protein cross-
reacting with the cyclin B1 antibody.
G Timecourse of DIA-induced cyclin A and B degradation, cross-checking levels of each mitotic cyclin. Treatments were performed as for DIA-treated panels in (E). Cell
extracts were checked for both cyclin A2 and B1 levels following DIA addition (* indicates non-specific band).
H Comparison of DIA and siRNA depletion. Cells were treated with DIA for 4 h or pre-transfected with CycB1 SMARTpool siRNAs 48 h earlier. Cell extracts were
analysed by immunoblotting for cyclin B1 (L.E, long exposure, S.E. short exposure) using the same mouse monoclonal antibody as in (E) and (F).
(I) Assaying cyclin B1 depletion in mitotic cells using a rabbit monoclonal antibody. Extracts from asynchronous or mitotic cells were collected and analysed by
immunoblotting using the indicated antibodies.
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A2 had no impact on cyclin B1 levels and vice versa in the 4-h time-
scale of the depletion experiments (Fig 1G). Moreover, DIA-induced
depletion of cyclin B1 was comparable to the levels of depletion
using a pool of four siRNAs 48 h after transfection (Fig 1H).
Degron-induced depletion of cyclin B1 was further verified using a
separate antibody (Fig 1I).
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Either cyclin B1 or B2 is sufficient to allow proliferation of RPE-1
cells, while cyclin A2 is essential for viability and mitotic entry
We aimed to further reduce the levels of B-type cyclins in these cells
and disrupted the CCNB2 gene (encoding for cyclin B2) in B1dd cells
by CRISPR editing, producing B1dd/B2ko cells. We verified absence
of cyclin B2 by immunoblotting (Fig 2A) and genome sequencing of
the targeted locus (see Materials and Methods section). To investi-
gate the long-term penetrance of this depletion system, we further
analysed A2dd, B1dd and B1dd/B2ko cells by measuring the distribu-
tion of cell cycle phases in asynchronous cells, 24 h after DIA treat-
ment (Fig 2B and C) and long-term proliferation using colony
formation assays (Fig 2D). Loss of cyclin A2 caused an accumula-
tion of the 4N population and prevented cell proliferation, but
depletion of cyclin B1 had no discernible effect on the cell cycle
phase distribution of RPE-1 cells and only reduced but not
prevented colony formation. However, B1dd/B2ko cells showed an
accumulation of 4N cells and a block in proliferation following DIA
treatment (Fig 2B–D) suggesting that these two mitotic cyclins can
compensate for each other to support cell viability.
We next measured mitotic entry dynamics in cells following DIA
depletion (unless otherwise indicated, DIA treatment for the remain-
ing MS indicates 4-h treatment in asynchronous cells) of either
cyclin A2 or both B1 and B2 (Figs 2E and EV1). DIA-treated A2dd
cells ceased to enter mitosis rapidly following drug addition, while
lack of cyclin B1 and B2 did not measurably affect the dynamics of
mitotic entry. However, these cells had severe defects in mitotic
progression and cell division (see below). We also tested if cyclin
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B3 could account for mitotic entry observed in the absence of cyclin
B1 and B2. However, we could not detect cyclin B3 protein in these
cells by immunoblotting despite the presence of the mRNA of this
cyclin. Moreover, siRNA depletion of the cyclin B3 mRNA in combi-
nation with DIA treatment of B1dd/B2ko cells did not appear to
reduce the number of mitotic cells (Fig 2F and G). Taken together,
these results suggest that cyclin A2 is essential to initiate mitosis
and that B-type cyclins are not rate-limiting for mitotic entry.
Previous experiments suggested that mouse embryonic fibrob-
lasts could proliferate in the absence of cyclin A2, yet it appears to
be essential in RPE-1 cells (Kalaszczynska et al, 2009; Gopinathan
et al, 2014). To address these differences, we analysed the effects of
cyclin A2 depletion in two breast epithelial cell lines, one cancerous
(MCF7) and one un-transformed (MCF10A). Following 72 h of
depletion, cyclin A2 levels were substantially reduced (Fig 2H) and
these cells appeared to have undergone endoreplication as judged
by the increase in the > 4N population (Fig 2I). A similar increase
in the > 4N population was observed in RPE-1 OsTIR1 cells follow-
ing 72 h cyclin A2 depletion, while DIA-mediated degron depletion
alone, or in combination with cyclin A2 siRNA caused an increase
in the 4N but not > 4N population of RPE-1 cells (Fig 2J and K).
These data suggest that cyclin A2 is critical for cell cycle control in
several epithelial cell lines. They also demonstrate that due to either
slow, or incomplete depletion of cyclin A2 by siRNA, cells undergo
endoreplication. In contrast, rapid and acute cyclin A2 depletion
results in the accumulation of the 4N population, but does not cause
a significant increase in endoreplication.
Cyclin B is essential for sister-chromatid segregation
and cytokinesis
We subsequently analysed the phenotypes of cells lacking B-type
cyclins in closer detail. DIA-treated B1dd/B2ko cells readily entered
mitosis, but failed to undergo sister-chromatid segregation and
cytokinesis (Figs 3A and EV2). Indeed, in more than 150 mitotic
events observed, we did not record a single successful example of
normal mitotic exit in cells lacking cyclin B1 and B2, while cells
lacking either B1 or B2 alone did not have apparent mitotic defects.
Even in cases where DIA-treated B1dd/B2ko cell-initiated segregation
and cytokinesis, all cells ultimately failed cell division, resulting in a
single bi-nucleated daughter cell. A fraction of these cells did not
transit prophase and exited mitosis without undergoing NEBD.
Moreover, we observed a delay in mitotic progression following DIA
treatment (Fig 3B). To analyse this phenotype with improved reso-
lution, we recorded mitotic progression in B1dd/B2ko cells that
stably expressed Fusion Red-Histone H2B and the kinetochore
component Mis12-GFP. Figure 3C shows a typical example of
mitotic progression in cells with or without B-type cyclins (see also
Movie EV1 and EV2). While cells lacking cyclin B can clearly initiate
chromosome condensation, NEBD and spindle formation, they fail
to segregate their sister chromatids and exit mitosis with a single
fragmented nucleus.
A simple explanation for this failed mitotic exit could be the
early degradation of cyclin A2 by the APC/C that is independent of
the SAC. However, we observed a distinct mitotic defect in cells
lacking cyclin B1/2 (Fig 3D) that were arrested in mitosis by a
APC/C inhibitor cocktail, proTAME/Apcin (Sackton et al, 2014).
Overall, we observed an enrichment in prophase, and prometa-
phase (or defective metaphase) after DIA treatment and APC/C
inhibition, but failed to identify DIA-treated cells with a clear meta-
phase alignment. Accordingly, we observed a small but significant
decrease in the level of phosphorylation at Ser-Pro residues follow-
ing DIA treatment as judged by quantitative immunofluorescence
(Fig 3E).
ProTAME/Apcin was effective in stabilising cyclin A, as judged
by accumulation of this protein in SAC arrested RPE-1 cells
◀ Figure 2. Cell proliferation in the absence of cyclin A2 and B-type cyclins.A Cyclin B2 knock-out and induced degradation by immunoblotting. Indicated cell lines were analysed 24 h after mock or Dox/IAA/Asv (DIA) treatment using the
indicated antibodies to confirm homozygous gene tagging and efficiency of protein degradation.
B Cell cycle analysis 24 h after DIA treatment. Cells were analysed by EdU labelling, PI staining and FACS analysis. The histograms show the PI intensities while the dot
plots show EdU incorporation (y-axis) vs PI intensity (x-axis). Gating of cell cycle phases is indicated by colour (G1—black, S phase—green, G2/M phase—orange)
C Cell cycle phase frequencies quantified from flow cytometry data (shown in (B)) in indicated cell lines 24 h after DIA treatment, (n = 3 experiments, s.d. indicated by
error bars).
D Cell proliferation of A2dd, CycB1dd and B1dd/B2ko following mock or DIA treatment. One thousand cells were plated in each well (diameter 3.5 cm) and incubated for
10 days before methanol fixation and Crystal Violet staining.
E Kinetics of mitotic entry as measured by time-lapse microscopy in A2dd and B1dd/B2ko cells following mock or 4-h DIA treatment of asynchronous cells. The cells were
imaged for 16 h with 5-min intervals using widefield DIC; mitotic entry was manually scored by detecting cell rounding. Curves display the cumulative mitotic index
(data from three repeats, n > 500 cells per condition, s.d. indicated by shaded area).
F qPCR analysis of cyclin B3 mRNA levels, following 72-h depletion in B1dd/B2ko cells. For quantification, we used primers to amplify two control mRNAs, TATA-binding
protein and actin. The plot shows the levels of CycB3 siRNA-depleted mRNA relative to Ctr siRNA-transfected cells. (Bars indicate the mean of three independent
experiments; error bars indicate the standard deviation between these three repeats.)
G Mitotic index measurements of B1dd/B2ko cells with the indicated treatments. Cells were transfected with siRNA for 72 h; after 36 h, they were blocked for 24 h with
Thymidine and fixed 12 h after release from Thymidine. ProTAME and Apcin were added for the final 2 h before fixation. Mitotic cells were scored based on DAPI
staining and on condensed chromosome formation. The bar plots show mean values of three biological repeats (n = 100 per repeat and sample, error bars indicate
standard deviation, and P-values were calculated using an independent two-sample t-test).
H Cyclin A2 siRNA depletion in MCF7 and MCF10A cells. The cells were transfected with Ctr or cyclin A2 siRNA for indicated length of time and probed for cyclin A2
levels by immunoblotting.
I Cyclin A2 siRNA depletion causes endoreplication. Following 72 h of siRNA transfection, MCF7 and MCF10A cells were analysed by PI staining and FACS. The
histograms show the changes in DNA content (PI Int.) towards > 4N following cyclin A2 depletion.
J Cyclin A2 siRNA and degron depletion in RPE-1 cells. RPE-1 OsTIR1 and RPE-1 A2dd cells were subjected to 72 h of cyclin A2 siRNA depletion and/or of DIA treatment
as indicated and probed for cyclin A2 levels by immunoblotting. The longer exposure (L.E.) reveals incomplete depletion of cyclin 2 by siRNA.
K Cyclin A degron depletion causes accumulation of cells in G2 phase. Following 72 h of siRNA transfection or DIA treatment, RPE-1 OsTIR1 and A2dd cells were
analysed by PI staining and FACS. The histograms show the changes in DNA content (PI Int.) towards > 4N following cyclin siRNA A2 depletion in RPE-1 OsTIR1 cells,
while DIA treatment in A2dd cells does cause an increase in the 4N but not > 4N peak.
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following proTAME/Apcin treatment (Fig 3F). This phenotype was
unchanged, even in cells depleted of the essential APC/C subunit
Cdc27 and simultaneously treated with APC/C inhibitors, further
suggesting that stabilising cyclin A does not rescue the spindle
defects caused by cyclin B depletion (Fig 3G). A typical example of
a mitotic spindle in proTAME/Apcin-arrested DIA-depleted cyclin
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B1dd/B2ko cells is shown in Fig 3H. Our observation that cells lack-
ing cyclin B1 and B2 can progress to prometaphase agrees with
previous reports based on siRNA depletion experiments (Chen et al,
2008; Gong & Ferrell, 2010). To further increase the level of cyclin B
depletion and to rule out incomplete gRNA/Cas9-mediated gene
depletion of cyclin B2, we combined cyclin B1/2 siRNA- and
degron-induced degradation, reasoning that mRNA and protein
depletion are expected to synergise. However, even in the case of
combined siRNA and degron depletion, we did not see a reduction
in mitotic index or changes in the spindle phenotypes (Fig 3I–K).
This further supports the notion that substantial depletion of B-type
cyclins does not affect mitotic entry dynamics, but prevents the
establishment of metaphase alignment and sister-chromatid segrega-
tion.
Exposure to ice-cold medium revealed intact K-fibres in DIA-
treated B1dd/B2ko cells, and re-exposure to warm medium resulted
in the reformation of a disorganised spindle with extended astral
microtubules (Fig 3L). We also used the centromere/kinetochore
markers CenpA and CenpB to assess bi-orientation and segrega-
tion of sister chromatids (Fig EV3). The markedly reduced
distance between sister centromeres following DIA treatment
suggests lack of tension. Moreover, we frequently observed
unseparated centromere pairs in cells that were exiting mitosis, as
judged by attempted furrow formation, indicating that separase
activation and/or microtubule force generation was impaired in
these cells. These distinct phenotypes suggest that while cyclin B
is required for specific regulatory events to coordinate the meta-
phase/anaphase transition, it is not essential for the establishment
of the mitotic state.
Cyclin A2 is required in G2 phase to trigger mitotic entry
Previous reports implicated cyclin A2 in triggering M phase via
Cdk1 activation (Fung et al, 2007; Gong & Ferrell, 2010), but could
not differentiate between knock-on effects of DNA replication prob-
lems and G2-specific functions of cyclin A2. We took advantage of
the A2dd cells to address this question by performing G2-specific
depletion of cyclin A2. For this purpose, we used a PCNA-mRuby
fusion (Zerjatke et al, 2017). PCNA forms foci in S phase but these
replication structures dissipate upon completion of DNA replication
(Leonhardt et al, 2000) (Fig 4A). This allowed us to identify cells
that were DIA-treated after completion of S phase. This effectively
blocked further progression into mitosis (Fig 4B), suggesting that
either the presence, or new synthesis of cyclin A in this cell cycle
phase is required for mitotic entry. To further support this notion,
we performed EdU pulse labelling at the time of DIA treatment,
followed by fixation and CENP-F immunofluorescence 4 h later to
mark cells that were in G2 phase (CENP-F-positive/EdU-negative)
when induced cyclin A2 degradation began (Fig 4C). This resulted
in an accumulation of cells that had been in G2 phase at the time of
DIA treatment, further supporting a G2-specific role for cyclin A2.
Inhibition of Wee1 with the small molecule inhibitors MK1775
(Hirai et al, 2009) or PD-166285 (Wang et al, 2001) was sufficient
to overcome this block and resulted in resumption of mitotic entry
with kinetics comparable to the controls (Fig 4D–F). Once the G2
block was overcome by Wee1 inhibition, cells lacking cyclin A could
form a metaphase spindle and undergo chromosome segregation
and cell division after delaying mitotic progression in metaphase for
~ 20 min (Fig 4F). Likewise, siRNA depletion of B55 alpha and delta
◀ Figure 3. Cyclin B is essential for sister-chromatid bi-orientation and segregation.A Frequency of mitotic phenotypes observed in indicated cell lines with or without DIA treatment (three repeats, n > 50 per repeat, error bars indicate s.d.). DIA was
added for 4 h in asynchronous cells followed by 12 h of imaging.
B Mitotic duration comparing mock-treated and DIA-treated B1dd/B2ko cells. Time of entry and exit was defined by chromosome condensation and decondensation
(three repeats, n > 50 per repeat, the boxplot indicates median, first and third quartile and minimum/maximum values).
C Representative images from live-cell imaging of SiR-Tubulin-labelled (red) mitotic B1dd/B2ko cells expressing FusionRed-H2B (green), Mis12-GFP (white); time in mins,
scale bar = 5 lm. Cells were imaged 4 h after DIA treatment.
D Characterisation of mitotic spindle in proTAME/Apcin (P/A) arrested B1dd/B2ko cells with or without DIA treatment (three repeats, n > 50 per repeat, error bars
indicate s.d.). For cell synchronisation (P/A synchronisation), we released from 24-h Thymidine block into DIA- or PBS-containing medium and added (P/A) 10 h after
release. APC/C inhibition lasted for 2–4 h and was followed by fixation and immunofluorescence analysis.
E Intensities of anti-(pSP) antibody staining in cells treated as in (D) (three repeats, n > 50 per repeat). Key to legend: I-DIA = control interphase cells, M-DIA,
M + DIA = control and DIA-treated mitotic cells. The boxplot indicates median, first and third quartile and minimum/maximum values; numbers below panel
indicate the median values calculated from each data set.
F Cyclin A2 levels were assessed by immunoblotting after 18 h in 100 ng/ml nocodazole and/or 5 lM STLC. 6 lM proTAME was added to the indicated samples for the
final 6 h.
G Upper panel, confirmation of Cdc27 depletion by immunoblotting 72 h after siRNA transfection in B1dd/B2ko cells. Lower panel, following 40-h siRNA transfection,
B1dd/B2ko cells were treated for 24 h with Thymidine, released for 10 h and treated with proTAME and Apcin for additional 4 h. At this point, the cells were fixed and
stained with tubulin and pericentrin for immunofluorescence analysis. Data are mean values from 3 independent repeats (n > 50 for each repeat); error bars show
standard deviation.
H Representative images of mitotic spindles in control- and DIA-treated B1dd/B2ko cells following arrest in mitosis by proTAME/Apcin treatment (as in D). Tubulin
staining is shown in white, pericentrin in green and DAPI in red, scale bar = 5 lm.
I Confirmation of cyclin B1 and B2 depletion 48 h after siRNA (pool of four different siRNAs) depletion by immunoblotting in WT RPE-1 cells. Asterisks indicate non-
specific bands that are not targeted by siRNAs.
J Additional siRNA depletion of CycB1 and B2 in Ctr- and DIA-treated B1dd/B2ko cells does not prevent mitotic entry. Cells were released from a 24-h Thymidine arrest
for 10 h at which point proTAME/Apcin were added for an additional 6 h before fixation, Hoechst staining and mitotic index scoring. Data are mean values from
three independent repeats (n > 100 for each repeat); error bars show standard deviation.
K Additional siRNA depletion of CycB1 and B2 in Ctr- and DIA-treated B1dd/B2ko cells does not change the mitotic phenotypes caused by DIA depletion. Cells were
treated as in (E) and stained with tubulin and pericentrin for immunofluorescence analysis. Data are mean values from three independent repeats (n > 50 for each
repeat); error bars show standard deviation.
L Immunofluorescence images from mitotic Ctr- and DIA-treated B1dd/B2ko cells after P/A synchronisation stained with anti-alpha-tubulin (green), anti-gamma-tubulin
(red) antibodies and DAPI (blue), scale bar = 5 lm. Cells were exposed to ice-cold medium and either fixed immediately after cold exposure, or incubated for 5, 10, or
20 min at 37°C before fixation.
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resulted in a partial rescue of mitotic entry in DIA-treated A2dd cells
following release from a Thymidine arrest (Fig 4G and H).
Nuclear cyclin B1 partially compensates for S and G2 defects in
cells lacking cyclin A2
We went on to analyse the effects of acute cyclin A depletion on cell
cycle progression using an Edu pulse-chase experiment. We labelled
asynchronous A2dd cells with EdU after 4-h DIA treatment, removed
the EdU from the medium and followed these cells for 12 additional
hours (Fig 5A–C). This analysis revealed that DIA-treated A2dd cells
can progress from G1 to S phase (cells accumulating in Gate 1), but
do not progress from G2 phase to the next G1 phase (cells leaving
Gate 2). Moreover, we observed a significant delay in the progres-
sion from early S phase (Gate 3) to mid (Gate 4)- and late (Gate 5) S
phase. Cyclin A2-depleted cells that were in S phase at the time of
EdU labelling did not undergo cell division to reach the next G1
phase in the subsequent 12 h (re-accumulation of cells in Gate 3).
Taken together, these data suggest that cyclin A2 is critical both for
the G2/M transition and also to complete DNA replication, but not
essential for progression from G1 to S phase.
We next addressed, if an increased expression of cyclin B1 can
compensate for the loss of cyclin A. We generated constructs to
express YFP, cyclin B1-YFP (B1-WT), and also targeted cyclin B1 to
the nucleus by fusing it with a SV40 nuclear localisation sequence
(Collas & Alestro¨m, 1996) (B1-NLS). We used the sleeping beauty
transposon system (Kowarz et al, 2015) to engineer existing A2dd and
B1dd/B2ko cell lines by incorporating the constructs with a doxycy-
cline-inducible promoter into the genome. This allowed us to rapidly
deplete the endogenous cyclin A2 or B1 and compensate this with
newly expressed cyclin B1 tagged with either YFP or YFP-NLS
(Figs 5D and EV4). Both WT and nuclear cyclin B1 showed the
expected cytoplasmic and nuclear localisation and fully reverted the
sister-chromatid segregation and cytokinesis defects in DIA-treated
B1dd/B2ko cells (Fig EV4). This suggested that both incorporated
constructs are generating functional cyclin B1, whereas the YFP
control showed no difference in phenotype, as expected. We then
analysed the effects of induced cyclin B1-YFP expression in DIA-
treated A2dd cells using the same EdU pulse-chase assay described
above (Fig 5E and H). Induced expression of YFP alone did not
change the cyclin A2 depletion phenotypes and led to a delay in S-
phase progression and a block in the appearance of new G1 cells,
while in WT cells over 80% of Edu-positive cells progressed into the
next G1 phase. Both WT and nuclear cyclin B1-YFP could induce a
reversion of this phenotype with about 10% of cells reaccumulating in
the next G1 phase with WT cyclin B1-YFP and 30% with nuclear
cyclin B1-YFP. We then analysed progression of these cells following
release from a Thymidine arrest by live-cell imaging (Fig 5F). Similar
to the pulse-chase analysis, nuclear cyclin B1-YFP was approximately
threefold more successful than WT cyclin B1-YFP in replacing cyclin
A2. Cells expressing nuclear cyclin B1-YFP could promote cell division
at a rate of ~ 50% lower compared to cells expressing endogenous
cyclin A2. Similar to the A2dd cells treated with Wee1 inhibitors, we
observed a significant delay in metaphase when mitosis was induced
by over-expressed cyclin B1 in cyclin A2-depleted cells (Fig 5G).
These data suggest that cyclin A2 is required for both completion
of DNA replication and initiation of mitosis. These defects can be
partially compensated by nuclear cyclin B1, suggesting that the
nuclear localisation is a key factor in explaining the essential func-
tions of cyclin A2, as previously suggested by siRNA depletion
experiments (Gong et al, 2007). Cells entering mitosis in the absence
of cyclin A2 are partially defective in mitotic progression suggesting
additional functions of this cyclin in orchestrating sister-chromatid
segregation, as previously suggested (Kabeche & Compton, 2013;
Dumitru et al, 2017). One possible consequence of cyclin A2 deple-
tion could be that free Cdk2 sequesters cyclin B thereby generating
a dominant negative effect on mitotic entry. This is unlikely to be
the case for the observed G2 arrest, because cyclin B1-YFP immuno-
precipitates did not show an increase in co-precipitated Cdk2
(Fig 5I).
Cyclin B is required for the phosphorylation of a specific subset
of proteins in mitosis
Given the failure of cells lacking cyclin B to align the metaphase
spindle and to initiate sister-chromatid segregation, we aimed to
further quantify the contribution of cyclin B to mitotic phosphoryla-
tion events. To this end, we identified cyclin B-specific substrates
◀ Figure 4. Cyclin A2 is essential to trigger mitotic entry in G2 phase.A Time-lapse images of PCNA-mRuby-tagged A2dd cells. The imaging sequence was started at the time of doxycycline addition, and degron activity was triggered 3 h
later by addition of IAA and Asv or PBS (indicated by dashed line). Time is shown as hh:min; scale bar equals 10 lm. For further analysis, cells were chosen that had
dissipated their PCNA foci before the addition of DIA to ensure that cyclin A2 degradation was triggered in G2 phase.
B Single-cell analysis of 40 cells per condition treated as described in (A); each line represents the timing of G2/M/G1 progression for a single cell.
C A2dd cells were pulsed with EdU to label S phase then protein degradation was induced by DIA addition for 5 h and before fixation and Edu/CENPF/DAPI staining.
Cells that were in G2 at the time of DIA or mock treatment were identified as CENPF-positive, EdU-negative. Mitotic cells were excluded based on nuclei morphology.
The bar plots show mean percentage of EdU-negative/CENPF-positive cells of three repeats; error bars indicate standard deviation.
D Images from time-lapse sequence of mitosis showing cell division in controls and after addition of 0.5 lM PD-166285 in DIA-treated A2dd labelled with SiR-DNA (time
is indicated as hh:min; the scale bars represent 20 lm).
E Accumulative index of mitotic entry measured by time-lapse microscopy in A2dd cells following mock or DIA treatment and addition of Wee1 inhibitors MK1775
(1 lM) or PD-166285 (0.5 lM). Asynchronous cells were DIA-treated for 4 h and then imaged for 6 h in 5-min intervals. (Data from three repeats, n > 500 cells per
condition; standard deviation is indicated by shaded area).
F Quantification of metaphase duration in A2dd cells treated with DIA and Wee1 inhibitors as indicated (n > 50 per repeat, the boxplot indicates median, first and third
quartile and minimum/maximum values.)
G A2dd cells were transfected with Ctr or B55a/d siRNA. Forty-eight hours after transfection, the cells were treated with Thymidine for 24 h and then released. Ten
hours later, the cells were probed for B55 depletion by immunoblotting using a pan-B55 monoclonal antibody.
H Lack of B55 partially rescues mitotic entry in DIA-treated A2dd cells. Cells transfected with Ctr siRNA or B55a/d siRNA as in (B) were released from Thymidine, mock- or
DIA-treated and analysed by widefield live-cell imaging 8 h after the release. The cells were imaged every 10 min for 15 h and manually scored for mitotic index. The
lines represent mean values of three independent experiments, and standard deviation is indicated by the coloured areas (n > 100 per experiment).
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by comparing the phospho-proteome in mitotic control and DIA-
treated B1dd/B2ko cells (Fig 6A–C). We quantified differences in
phosphorylation in 5,670 phosphorylation sites (Table EV1),
including 2,351 that have a [S/T]-P motif in the peptide sequence
detected, and identified 197 sites in 137 substrates that were
reduced by ~ 2-fold or more. Thus, cyclin B depletion causes a
significant but relatively minor effect on the majority of mitotic
phosphorylations. We observed a more dramatic reduction in phos-
phorylation of only ~ 3.5% of the phospho-proteome and ~ 5.6%
of the proline-directed sites (131/2,351). These substrates were
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predominantly cytoskeletal and chromatin-associated proteins
(Fig. 6D). A more detailed network analysis (Fig EV5) identified a
variety of mitosis-associated processes that involve cyclin B-specific
substrates, including chromosome structure, microtubule (MT)
dynamics and cytokinesis.
To test if this set of cyclin B-specific phosphorylation sites corre-
lates with specific mitotic functions for cyclin B, we analysed the
localisation of a group of cyclin B-specific targets identified in the
screen. For this purpose, we chose Ki-67, the chromosome passenger
complex (CPC) members INCENP and Borealin, CDCA2, Top2B and
Tpx2. Each of these proteins shows a significant loss of phosphoryla-
tion after DIA treatment in the mass spectrometry analysis (Fig 6E,
Table EV2). Ki-67 acts as a surfactant on condensed mitotic chromo-
somes (Cuylen et al, 2016) and is heavily phosphorylated by Cdk1 in
mitosis (Blethrow et al, 2018). Loss of cyclin B following DIA treat-
ment resulted in a loss of Ki-67 from the chromosome periphery
◀ Figure 5. Nuclear cyclin B1 partially compensates for cyclin A2.A FACS plots from EdU pulse-chase experiment. Cells were DIA- or mock-treated for 4 h and then labelled with EdU for 1 h. The EdU was then washed out and
samples were taken every 3 h for 12 h and analysed by EdU/PI staining and FACS. The top left panel shows the gates that were used for analysis. The quantifications
shown in the panels to the right are from three independent repeats of this experiment.
B Quantification of cells progressing into Gate 1 (top panel, new S-phase cells) and Gate 2 (bottom panel, G2 cells) over time. The lines represent the mean of three
experiments; the coloured areas indicate the standard deviation.
C Relative changes in the percentage of EdU-positive cells in gates 3, 4 and 5 (G1/early S, mid-S and late S/G2 phase). The bars indicate the relative mean values from
three independent experiments; the error bars represent the standard deviation.
D Cyclin A2dd cells with inducible CycB1-YFP (B1-WT) and CycB1-YFP-NLS (B1-NLS) were analysed for DIA-induced cyclin B1 expression/cyclin A2 depletion. Samples
were collected at indicated time points and probed by immunoblotting with cyclin B1 and cyclin A2 antibodies (* indicates non-specific band).
E Quantifications of EdU pulse-chase data as in (C) in DIA-treated cyclin A2 cells expressing B1-WT, B1-NLS or YFP as indicated. The bars indicate the relative mean
values from three independent experiments; the error bars represent the standard deviation.
F Accumulative mitotic index measurement of cyclin A2 cells following cyclin A2 depletions and induction of indicated cDNAs. The lines represent the mean of three
experiments; the coloured areas indicate the standard deviation.
G Quantification of metaphase duration in A2dd cells treated with DIA following induction of indicated proteins (n > 50 per repeat, the boxplot indicates median, first
and third quartile and minimum/maximum values).
H FACS plots from EdU pulse-chase experiment in A2dd cells following induction of indicated genes. Data are representative example for quantifications shown in (E).
I Immunoprecipitation of YFP from extract from A2dd following induction of YFP (Y), CycB1-YFP (BY) and CycB1-YFP-NLS (BYN). The samples in the odd lanes (IAA/Asv)
were treated with 1 lg/ml doxycycline alone, while samples in even lanes (IAA/Asv+) were treated with Auxin and Asv to induce cyclin A2 depletion. Total cell extract
and immune precipitates were probed by immunoblotting with the indicated antisera.
▸Figure 6. Mitotic cyclin B-dependent phosphorylation sites.A Cell synchronisation scheme: to obtain an optimal enrichment in mitotic cells, we pre-synchronised B1dd/B2ko cells by serum starvation for 48 h followed by a release
into Thymidine for 24 h. Cells were then released into S phase in the presence or absence of DIA and blocked in mitosis by the addition of proTAME. Mitotic cells
were collected by shake-off 12 h following the release.
B Phospho-proteomics workflow. Protein extracts were prepared from the indicated cells, digested with trypsin and labelled with 6-plex TMT reagents. The TMT-
labelled peptides were then mixed and subjected to fractionation by high pH reverse phase into 24 fractions. From each fraction, 95% was taken for phospho-
enrichment and 5% retained for analysis of unmodified peptides. For phospho-enrichment, the 24 fractions were combined into a total of 16 fractions. Samples
(unmodified and phospho-enriched) were then analysed by LC-MS/MS on an Orbitrap Fusion instrument using synchronous precursor selection (SPS). This analysis
resulted in detection of 11,234 phosphorylation sites, of which 5,670 were quantitated. The number of class I sites are indicated in brackets (site localisation
probability > 0.75).
C Quantification of cyclin B-specific substrates by phospho-proteomics. Phosphorylation sites deemed significantly changing are shown in red (P: 0.05, 1.96*standard
deviation fold change cut-offs, see Material and Methods).
D Gene ontology analysis of cyclin B-dependent substrates.
E Quantification of changes in selected cyclin B-dependent mitotic phosphorylations including Ki-67 (left panel), INCENP/Borealin (middle panel) and Top2B, CDCA2
and Tpx2.
F Representative images of Ki-67 immunofluorescent staining of chromosome spreads from control (Ctr) and DIA-treated P/A synchronised B1dd/B2ko cells and
quantification of Ki-67 staining intensity using cross sections of chromosomes (data from three repeats, n = 50, shaded area indicates standard deviation, scale
bar = 5 lm).
G Representative images from live-cell imaging of DIA-treated SiR-Tubulin-labelled (red) B1dd/B2ko cells expressing FusionRed-H2B (green) and AurB-GFP (white); time is
indicated in minutes, scale bar = 5 lm. Bottom panel shows frequencies of aberrant AurB localisation in P/A synchronised B1dd/B2ko cells. (Bars indicate mean of
three repeats, n = 50 cells per repeat; stdv is indicated by error bars.)
H CDCA2 is excluded from mitotic chromosomes in control cells while this exclusion is lost in DIA-treated B1dd/B2ko cells. The upper panel shows immunofluorescence
images; for quantification, we analysed fluorescence intensity across chromosomes. The data show the mean of 150 cells (from three repeats n = 50) and error bars
indicate standard deviation.
I Top2B levels in mitotic cells are increased in DIA-treated B1dd/B2ko cells. The left panel shows immunofluorescence images; for quantification, we segmented mitotic
DAPI staining, measured the mean intensity of Top2B staining and plotted the ratio between mitotic and interphase nuclei. (Bars indicate median, first and third
quartile; data are from three repeats, n = 50 cells per repeat.)
J Tpx2 shows reduced spread on mitotic chromosomes in DIA-treated B1dd/B2ko cells. The top panel shows immunofluorescence images; for quantification, we
measured the mean intensity of Tpx2 staining on the centrosomes and spindle and plotted the ratio of these values per cell. (Bars indicate median, first and third
quartile; data are from three repeats, n = 50 cells per repeat.) We also analysed the centrosome/spindle distribution of AurA that does not change following DIA
treatment.
Data information: For images in (H–J) the scale bar equals 10 lm.
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(Fig 6F), correlating with the marked decrease in multiple phospho-
rylations in Ki-67 in DIA-treated B1dd/B2ko cells. Likewise, INCENP
and Borealin have previously been identified as mitotic targets of
Cdk1 (Goto et al, 2005; Daub et al, 2008; Dephoure et al, 2008;
Tsukahara et al, 2010), but the cyclin B-specific phospho-sites that
we have identified here (T424 in INCENP and T106 in Borealin)
have, to our knowledge, not previously been related to CPC localisa-
tion and function. DIA treatment resulted in premature displacement
of a key CPC subunit, Aurora B-GFP, from the centromeres (Fig 6G,
Movie EV3 and EV4) in DIA-treated B1dd/B2ko cells, even when cells
were arrested in mitosis by APC/C inhibition (Fig 6G bottom panel).
CPC mis-regulation also correlates with the significant decrease in
histone H3 S10 phosphorylation, a target of AuroraB kinase activity
that we observed (Table EV2). Likewise, the reduction of phosphory-
lation of CDCA2, Top2B and Tpx2 following DIA treatment corre-
lated with changes in mitotic localisation (Fig 6H–J), further
validating the significance of our proteomic data set.
Regulation of mitotic PP1 and PP2A:B55 activity occurs
independently of cyclin B
Our proteomic analysis suggests that cells robustly buffer against
loss of Cdk1:cyclin B and allow the phosphorylation of roughly 90%
of mitotic Cdk1 substrates in the presence of a single mitotic cyclin,
namely cyclin A2. Given that Cdk1 is essential to trigger mitotic
phosphorylation and cyclin A2 is the major Cdk1 regulator that can
CDCA2
TOP2B
TPX2
T1287
T72
S486
S400
Serum 
Starvation
+Serum 
+Thymidine
48 hours 24 hours 12 hours
+ProTame
-/+DIA
-Thymidine
11,234 (7,355)  
detected
phosphosites
5,670 (4,781) 
quantitated 
phosphosites
126CycB-ON Rep1
127CycB-OFF Rep1
128CycB-ON Rep2
129CycB-OFF Rep2
130CycB-ON Rep3
131CycB-OFF Rep3
Trypsin
digest Mix
Ti:IMAC
phospho
enrichment
(16 fractions)High pHReverse Phase
(24 fractions)
LC-MS/MS
(SPS)
95%
5%
TMT
labeling
lo
g0
.0
5 
p-
va
lu
e
log2 Mean Fold Change
RNA
Cytoskeleton 27%
Chromatin 42% Membrane
Golgi/ER
Metabolism
Signalling
Ribosome
Other
INCENP
Borealin
T424
T106
Ki-67
log2 Mean Fold Change
lo
g0
.0
5 
p-
va
lu
e
Airyscan reconstructed, scale=5µm
Ctr Comb. Ctr Ki-67
DIA Comb. DIA Ki-67
0.0 0.5 1.0 1.5 2.0
Distance (µm)
0
20
40
60
80
100
120
140
In
te
ns
ity
 (A
.U
.) Ctr-DAPI
DIA-DAPI
Ctr-Ki-67
DIA-Ki-67
Airyscan reconstructed MIP, 
scale=5µm
0 
Ctr AurB-GFP
35
0 45
60
75
Ctr Merge
DIA Merge
DIA AurB-GFP
%
 m
ito
tic
 c
el
ls
0
Ctr DIA
10
20
30
40
50
On Centromere
Off Centromere
-6 -4 -2 0 2 4 6
0.5
1.0 -DIA
R
el
at
iv
e 
flu
or
es
ce
nc
e 
in
te
ns
ity
-6 -4 -2 0 2 4 6
0.5
1.0
0.0
0.5
1.0
1.5
2.0
R
at
io
 T
op
2B
R
at
io
 T
px
2
p < 0.0001
0.0
0.5
1.0
1.5
2.0
2.5 p < 0.0001
0.0
1.0
2.0
3.0
4.0
5.0 N.S.
TPX2 AurA DNA Merge
CDCA2 DNA Merge
+D
IA
+D
IA
-D
IA
-D
IA
+D
IA
-D
IA
CDCA2
DNA
Distance (µm)
Top2B DNA Merge
-DIA +DIA
-DIA +DIA -DIA +DIA
R
at
io
 A
ur
A
A
C
F G H I
J
D E
B
12 of 23 The EMBO Journal 39: e104419 | 2020 ª 2020 The Authors
The EMBO Journal Nadia Hégarat
- + - +
siCtr siE/A
DIA
pS67
ENSA/ARPP19
Cyclin B1
ENSA/ARPP19
GAPDH
80
100
190
0 20
Ctr
40 60 0 20 40 60
58
46
32
32
DIAmin 
after Cdk1i
pSP (Cdk substrates)
G
APDH
DIACtr
re
l. 
in
te
si
ty
p = 0.18
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Time
0
20
40
60
-DIA
55
72
A 0 30 60 120 A 0 30 60 120
95
180
34
34
+DIA
*
72
95
A B
C
E
D
log2 Mean Fold Change
PP1 (cat)
MASTL
ARPP19/ENSA
S512
S108
T320
S2
S109
S67
lo
g0
.0
5 
p-
va
lu
e
kDa
kDa
kDa
Cyclin B1
GWL
pT194
GWL
GAPDH
pPP1
pCdc27
17
17
55
32
Figure 7. Mitotic Greatwall, ENSA and PP1 regulation are independent of cyclin B.
A Quantification of Greatwall, ENSA/ARPP19 and PP1 phosphorylation based on phospho-proteomic data.
B Confirmation of ENSA/ARPP19 S67 phosphorylation in mitotic extracts from Ctr- and DIA-treated cells, before and after ENSA/ARPP19 siRNA depletion.
C Dynamics of mitotic substrate dephosphorylation triggered by Cdk1 inhibition in control and DIA-treated B1dd/B2ko cells. The cells were enriched in mitosis by
Thymidine release and proTAME/Apcin treatment and treated with 1 lM flavopiridol to trigger mitotic exit. Dephosphorylation was measured by probing the
immunoblots with anti Cdk1 substrate (anti-pSP) antibody.
D Three repeats of the experiment in (C) were quantified and corrected based on the corresponding GAPDH intensity values. The bar plots show the mean of three
experiments, and the standard deviation is indicated by error bars.
E Dynamics of Greatwall, PP1 and Cdc27 dephosphorylation following Cdk1 inhibition in proTAME/Apcin-treated mitotic cell extracts from Ctr- or DIA-treated cells. Cell
extracts were prepared at the indicated times following treatment with 1 lM flavopiridol and analysed by immunoblotting (* indicates non-specific band).
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compensate for cyclin B in late G2 phase, the observed cyclin B-
independent phosphorylation events are likely exerted by Cdk1:cy-
clin A2. The question remains: How cells can cope with loss of the
major mitotic kinase Cdk1:cyclin B and still readily phosphorylate
most of the mitotic phospho-proteome, including many bona-fide
Cdk sites? We hypothesised that this is due to the inactivation of
antagonising phosphatase PP2A:B55 in the absence of Cdk1:cyclin B
activation. This would suggest that there are two independent mech-
anisms to promote mitotic Cdk1 phosphorylation: (i) by activating
Cdk1:cyclin B, (ii) by activating Greatwall that will phosphorylate
ENSA/ARPP19 to inhibit PP2A:B55. In this case, Greatwall phospho-
rylation as well as the downstream phosphorylation of ENSA/
ARPP19 at Ser67 should be fully established in cells lacking B-type
cyclins. This notion is indeed supported by our phospho-proteomic
data (Fig 7A). We also readily detected ENSA/ARPP19 Ser67 phos-
phorylation in mitotic extracts of DIA-treated B1dd/B2ko cells
(Fig 7B). Moreover, dephosphorylation dynamics of various Cdk1
sites and overall Ser-Pro phosphorylations are not significantly
changed in proTAME/Apcin-arrested mitotic B1dd/B2ko cells follow-
ing Cdk inhibition, when Ctr- and DIA-treated cells are compared
(Fig 7C–E).
Greatwall and cyclin B synergise to trigger NEBD
If inhibition of PP2A:B55 is responsible for supporting mitotic phos-
phorylation in the absence of cyclin B, simultaneous depletion of B-
type cyclins and the Greatwall pathway should ultimately prevent
cells from entering mitosis. To test this hypothesis, we depleted
ENSA and ARPP19 from B1dd/B2ko cells and monitored mitotic
progression by time-lapse microscopy (Fig 8A, Movie EV5 and
EV6). Depletion of ENSA/ARPP19 did not prevent mitotic entry, but
resulted in sister-chromatid misalignment and cytokinesis defects,
as previously reported for cells lacking Greatwall. Cyclin B depletion
by DIA treatment caused similar mitotic exit phenotypes as
described above (Fig 3A–D). Surprisingly, cells with simultaneous
depletion of ENSA/ARPP19 and cyclin B appeared able to enter
prophase, as judged by cell rounding, centrosome separation and
compaction of the nucleus. However, these cells did not undergo
NEBD and often remained in this prophase-like state for a prolonged
period of time, before reverting to interphase (Fig 8A, bottom panel,
Fig 8B). This release from the prophase state could be either due to
APC/C activation or slow dephosphorylation of the prophase
substrates.
These results suggest that cells can enter prophase in the absence
of cyclin B and with high PP2A:B55 activity, but fail to move past
NEBD. To further substantiate this observation, we analysed the
mitotic state following ENSA/ARPP19 or Greatwall depletion in
mitotic B1dd/B2ko cells by immunofluorescence (see representative
images in Fig 8C). The mitotic index, as judged by cell rounding,
centrosome separation and chromosome condensation, was only
mildly reduced in the co-depleted cells (Fig 8D). However, more
than 90% of mitotic cells lacking both cyclin B and Greatwall or
ENSA/ARPP19 failed to undergo NEBD as judged by Lamin A/C
staining (Fig 8E). This reduction in cells undergoing NEBD was due
to PP2A:B55 activity, because co-depletion of Greatwall and B55a/d
resulted again in an increase in cells that reached the prometaphase
state (Fig 8F).
Quantification of various mitotic indicators further supported the
observation that cells with high PP2A:B55 and low Cdk1:cyclin B
activity reach prophase. Thus, levels of serine–proline phosphoryla-
tion were clearly increased compared to interphase cells and only
marginally decreased compared to control prophase cells (Fig 8G).
Phosphorylation of Lamin A/C S22, a residue that is phosphorylated
in late G2/early prophase (Ly et al, 2017), was detected at a level
comparable to control prophase and mitotic cells (Fig 8H). Like-
wise, centrosomes were at a stage of separation similar to controls
before NEBD (Fig 8I), suggesting that these cells indeed remained in
a prophase-like state without progressing past NEBD.
Discussion
Our results are summarised by a model (Fig 9A) that we tested by
numerical simulation (Fig 9B and C). We propose a simple ordering
mechanism for mitotic entry, based on the increasing requirement
for Cdk1:cyclin activity, and increasing levels of sensitivity to the
antagonising phosphatase activity. This fits well with a similar
biochemical model for the ordering of mitotic exit (Bouchoux &
Uhlmann, 2011; Cundell et al, 2016). Cyclin A2 in G2 phase is criti-
cal to trigger mitosis by counteracting Wee1 and PP2A:B55, because
either Wee1 inhibition or B55 depletion can overcome the G2 arrest
caused by cyclin A2 depletion. In the absence of Greatwall and
◀ Figure 8. Greatwall and cyclin B synergise in triggering NEBD but not prophase.A Representative images from live-cell imaging of siRNA-transfected B1dd/B2ko cells (FusionRed-H2B in red, SiR-Tubulin in white, scale bar = 10 lm). Bar plot panels on
the right show single-cell analysis of 10 cells manually scored for length mitosis pre-NEBD and post-NEBD. Entry into prophase was scored by cell rounding and
NEBD was identified by influx of Tubulin in the nucleus.
B Widefield imaging. DIC (Grey), SiR-DNA (b/w), of ENSA/ARPP19 siRNA-transfected DIA-treated B1dd/B2ko cells. Time is indicated in hh:min, scale bar = 10 lm.
C Panels of representative immunofluorescence images of siRNA-transfected and P/A-treated cells treated as indicated, scale bar = 10 lm.
D Quantification of mitotic index of siRNA-transfected P/A synchronised cells (See Fig. 4B for representative images; mean value of three repeats, n > 500 per repeat;
error bars indicate standard deviation).
E Quantification of mitotic B1dd/B2ko cells following siRNA transfection to deplete Greatwall (siGwl) or ENSA/ARPP19 (siE/A) and/or DIA treatment. Frequencies of
mitotic cells with intact (blue) and disassembled (red) Lamin A/C staining are plotted (mean value of three repeats, n > 50 per repeat; error bars indicate standard
deviation).
F As in (E) quantification of control- and DIA-treated mitotic B1dd/B2ko cells following siRNA transfection to deplete Greatwall and B55a/d. Frequencies of mitotic cells
with intact (blue) and disassembled (red) Lamin A/C staining are plotted (mean value of three repeats, n > 50 per repeat; error bars indicate standard deviation).
G Intensity of pSP-antibody staining in siRNA-transfected and DIA-treated B1dd/B2ko cells. The swarm-blots classify data from mitotic cells with intact (blue) or
disassembled (red) Lamin A/C.
H As in (G) intensity of anti-Lamin A/C pS22 antibody staining in siRNA-transfected and DIA-treated B1dd/B2ko cells.
I Same as in (G) and (H), data for centrosome distance in mitotic cells. Data for G-I are from three repeats, n > 50 per repeat; the bars indicate median, first and third
quartile as well as minimum and maximum values; data are from three repeats, n = 50 cells per repeat).
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cyclin B, cells enter a prophase state for several hours before revert-
ing back to interphase, due to either APC/C activation or dephos-
phorylation of Cdk1 substrates. This observation is reminiscent of
our recent report of a latent stable steady state that can be reached
in prophase (Rata et al, 2018). These early prophase substrates are
likely to be poor PP2A:B55 targets, or highly efficient Cdk1
substrates, and therefore require a low threshold of Cdk1:cyclin
activity. The next step in mitotic establishment, NEBD and transi-
tion to prometaphase, requires Greatwall-dependent PP2A:B55 inac-
tivation, or cyclin B-dependent increase in the levels of Cdk1
activity to phosphorylate the bulk of intermediate mitotic substrates.
We demonstrate that in the absence of cyclin B, Greatwall activation
is unperturbed and this allows progression of cells to prometaphase.
This is likely to depend on Cdk1:cyclin A that can phosphorylate
and activate Greatwall kinase in vitro (Mochida et al, 2016). Our
finding that cyclin B and Greatwall depletion has additive effects
suggests that they act in parallel, downstream of cyclin A to
promote mitotic phosphorylation. This explains how this regulatory
network is designed to allow buffering against fluctuations in kinase
and phosphatase activity during mitotic entry. It also explains the
lack of entry phenotypes in Greatwall and cyclin B-depleted cells. It
is noteworthy that mitotic entry in embryonic cell cycles is much
more reliant on both cyclin B and Greatwall (Castilho et al, 2009;
Strauss et al, 2018). A possible explanation for this difference could
be elevated levels of PP2A:B55 in these cells that have previously
remained in prolonged G2 arrests in form of immature oocytes.
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Figure 9. Numerical Model for cyclin A and B specific and overlapping functions during mitotic entry and progression.
A Influence diagram of the network controlling the phosphorylation of mitotic substrates. The auto-activation of CycB:Cdk1 and PP2A:B55 is controlled by inhibitory
phosphorylation and by the Greatwall-ENSA pathway, respectively. CycA:Cdk1 helps CycB:Cdk1 auto-activation and inhibits PP2:B55 activity through Greatwall
phosphorylation. Three different classes of mitotic substrates (early, intermediate and late) are distinguished based on their sensitivity to CycA:Cdk1, CycB:Cdk1 and
PP2A:B55.
B Final level of mitotic regulators and Cdk1-substrates in response to cyclin synthesis. The heat map is based on model simulations (C) starting with initial conditions
without cyclins (interphase, top row) until high and constant cyclin levels caused by APC/C inhibition.
C Numerical simulation of mitotic substrate phosphorylation network in response to rising cyclin levels. The model simulates mitotic entry experiments where cyclin
levels become stabilised by APC/C inhibition. Each row corresponds to one of the experimental conditions used in this work (control, CycA depletion etc.). Left
columns: cyclin levels and phosphorylated mitotic substrates (early, intermediate and late). Right columns: temporal changes of some mitotic regulators. Changes of
Cdc25-P and Gwl-P (not shown) are similar to phosphorylated ENSA (pENSA).
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Our study defines a final set of late substrates that strictly require
cyclin B-dependent Cdk1 activity. These phosphorylation events are
critical to initiate anaphase and cell division. The cyclin B-depen-
dent phospho-sites could be highly sensitive to Cdk1 counteracting
phosphatases or poor Cdk1 substrates and therefore require higher
levels of Cdk1:cyclin activity. Alternatively, defined localisation of
cyclin B could also contribute to the observed substrate specificity
and also further re-enforce localised Greatwall-dependent PP2A:
B55. The importance of cyclin B localisation is supported by recent
work (Alfonso-Pe´rez et al, 2019) showing a requirement for cyclin
B1 to phosphorylate Mps1 at the kinetochore and promote the SAC.
Our cyclin B1dd/B2ko cells will be a useful tool to further analyse the
requirements for cyclin B in SAC signalling. Likewise, future work
will need to establish the precise S-phase functions of cyclin A and
its contributions to initiating mitosis. The rapid induced degradation
system that we report here will be a helpful tool to further address
these questions for a better understanding of mammalian cell cycle
control mechanisms.
Material and Methods
Tissue culture and chemical reagents
hTERT RPE-1 cells were obtained from ATCC (cat. CRL-4000) and
were grown at 37°C with 5% CO2 in DMEM/F12 (Sigma-Aldrich)
media containing 10% foetal bovine serum (FCS) and 1% peni-
cillin–streptomycin. All cell lines were maintained by the GDSC cell
culture facility, regularly authenticated and tested for mycoplasma
infection.
Drugs used for this study and working concentrations were as
follows:
PD-166285 (0.5 lM; Stratech Scientific Limited, S8148-SEL).
Apcin (26 lM; Sigma-Aldrich SML1503).
ProTAME (6 lM; Bio-techne I-440-01M).
Asunaprevir (3 lM; BMS-650032, Bioquote, A3195).
Indole-3-acetic acid (IAA, 500 lM; Sigma-Aldrich I5148).
Doxycycline (1 lg/ml; Takara-bio, Clontech 631311).
Thymidine (4 mM; Sigma-Aldrich T1895).
SiR-DNA (50–100 nM; Tebu-bio Ltd. SC007).
SiR-Tubulin (50–100 nM; Tebu-bio Ltd. SC002).
Antibodies
A list of antibodies used in this study is provided in
Appendix Table S1.
Generation of endogenously tagged cell lines
gRNAs were designed using Benchling CRISPR tool (https://bench
ling.com/). The sequences 50 ACTAGTTCAAGATTTAGCCA 30, 50
TGTTTCTAAAACCATCAAGT 30, 50 GCACACTCACCGTCGGGCGT 30
and 50 GACCTGCTACAGGCACTCGT 30 were chosen for cyclin B1,
cyclin A2, cyclin B2 and Rosa26, respectively, and introduced into the
vector pSpCas9(BB)-2A-Puro (PX459) V2.0 following the protocol
described in Ran et al (2013). PX459 acquired from Feng Zhang via
Addgene (plasmid # 48139). Indel mutations in cyclin B2 were
confirmed by Sanger sequencing as two frameshift mutations down-
stream of the initiating ATG in the CCNB2 gene (CTCGACG-C
CCGACG-GTGAG and CTCGACGCC-C-GACGGTGAG with the missing
residues marked by hyphenation). The puromycin resistance in
hTERT RPE-1/OsTIR1 cells was removed using CRISPR using the
following gRNA sequence: 50 AGGGTAGTCGGCGAACGCGG 30. To
make the targeting template, Gibson assembly was used to assemble
into NotI-digested pAAV-CMV vector (gift from Stephan Geley,
University of Innsbruck, Austria) the fragments in the following order:
the left arm, a linker (50 CGCCTCAGCGGCATCAGCTGCAGGAGCTGG
AGGTGCATCTGGCTCAGCGGCAGG 30), mAID 3, SMASh 5, T2A-
neomycin and the right arm. To get CRISPR-resistant constructs, the
following sequences were mutated as followed: ACTAGTTCAAGATT
TAGCCAAGG by AtTAGTcCAgGAccTAGCtAAaG for cyclin B1 and
CCATCAAGTCGGTCAGACAGAAA by CCATgAtGaCGcTCAcACAGttA
for cyclin A2. Mutations (lowercase letters) are silent and preferential
codon usage was taken into account. For inducible expression of
OsTIR1, we used the construct described in Natsume et al (2016),
combined it with a bleomycin/zeocin resistance marker and cloned it
into a Rosa26 targeting construct. Integration was confirmed by
genomic PCR (Fig 1B and C). To generate stable clones, 106 hTERT
immortalised RPE-1 cells were transfected with 0.5 lg of gRNA/Cas9
expression plasmid and 1.5 lg of targeting template using Neon trans-
fection system (Invitrogen), with the following settings: 10-ll needle,
1,350 V, 20 ms and two pulses. Clones were incubated for 3 weeks in
media containing 1 mg/ml of neomycin (Sigma-Aldrich), 5 lg/ml
blasticidin (Gibco) or 500 lg/ml zeocin (Invivogen) and selected
clones were screened by Western blot.
Generation of PCNA-tagged cell lines
AAV-293T cells (Clontech) were seeded into a T75 flask 1 day
before transfection, such that they were 70% confluent on the day
of transfection. Cells were transfected with 3 lg each of pAAV-
mRuby-PCNA (Zerjatke et al, 2017) pRC and pHelper plasmids, and
20 ll Lipofectamine 2000, diluted in 3 ml OPTIMEM (Gibco). Lipo-
fectamine/DNA mixture was added to cells in 7 ml of complete
medium (DMEM with 10% FBS and 1% penicillin–streptomycin).
Cells were incubated at 37°C for 6 h before medium was replaced
with 10 ml of complete medium. Three days post-transfection,
medium and cells were transferred to a 50-ml falcon tube. Cells
were lysed with three rounds of freeze–thaw. The sample was
centrifuged at 10,000 g for 30 min at 4°C. Supernatant containing
AAV particles was collected and either used immediately or
aliquoted and stored at 80°C. cyclin A2dd cells were plated 1 day
before transduction, such that they were 40% confluent for trans-
duction. Cells were washed twice in PBS and incubated in 5 ml of
complete medium plus 5 ml of AAV-mRuby-PCNA containing super-
natant for 48 h. Cells were expanded for a further 48 h followed by
FACS sorting using a BD FACSMelody sorter according to the manu-
facturer’s instructions.
Generation of cell lines stably expressing fluorescent
protein markers
For rapid generation of multiple fluorescent protein-tagged cellular
markers, we cloned a sequence of P2A-ScaI-mEmeraldT2A-Balsticidin
resistance marker into the pFusionRed-H2B expression construct
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(Evrogen, FP421). The ScaI site was then used to clone Mis12 and AurB
in-frame with the preceding P2A and the following T2A sequence.
Cyclin A2dd and B1ddB2ko cells were transfected with 2 lg of the
expression plasmids by NEON electroporation (Invitrogen) and grown
for 2 weeks in medium containing 5 lg/ml blasticidin (Gibco). Fluo-
rescent protein expressing cell lines were isolated by FACS sorting
using a BD FACSMelody sorter according to the manufacturer’s instruc-
tion.
Generation of sleeping beauty cell lines
TET-on Sleeping beauty plasmid was obtained from Addgene (plas-
mid nr. 60496 pSB-tet-BP) with a blue fluorescent protein (BFP)
selection marker.
The plasmid originally contains Luciferase which was replaced
by the ORF of cyclin B-YFP and cyclin B-YFP-NLS fusions using NEB
HiFi Assembly. We used BspDI and NcoI sites to cut out the luci-
ferase and incorporated our GOI. 1.9 lg of this plasmid along with
100 ng transposase enzyme SB-100X (Addgene plasmid nr. 34879)
was transfected into RPE-1 degron cells using electroporation. After-
wards, cells were grown for 10 days and FACS sorted into a 96-well
plate for BFP expression (excitation ~ 456 nm) using FACSMelody
sorter according to the manufacturer’s instructions. Cells were then
grown up and analysed for protein expression after doxycycline
addition using immunoblotting.
Genomic PCR
Genomic DNA was extracted using DNeasy Blood and Tissue Kit
(Qiagen) according to the instructor’s recommendation; then, DNA
was amplified with Phusion High Fidelity DNA polymerase (New
England Biolabs) using the following primer pairs to check genomic
integration: 50 CTGCATTCTAGTTGTGGTTTGTCCA 30 and 50 ACT
ATGACCCACGCAGTACAA 30 (TetON-OsTIR1 into Rosa26 locus), 50
ATTGCTGAAGAGCTTGGCGG 30 and 50 TCACACCATTCAAGCACC
TGTA 30 (degron tags into cyclin A2 locus), 50 CTGAGCGGAAAACC
TGCTATC 30 and 50 CTGAACGAACAGGGGAAATGGTT 30 (degron
tags into cyclin B1 locus), 50 TGGTGGAAGATTGGTGGCTC 30 and 50
CTGCTTCTGGCATGGCTTTC 30 (internal amplification control in
Kif23 locus). Samples were loaded onto 1% agarose gel (Fisher) in
1× TAE buffer and containing ethidium bromide then imaged using
Ingenius, Syngene Bio-imaging apparatus.
RT–qPCR
cDNA was prepared from extracted mRNA (RNeasy kit, Qiagen)
using oligo d(T) (Ambion), murine RNase inhibitor (New England
Biolabs) and M-MuLV reverse transcriptase (New England Biolabs)
following the manufacturer’s directions. Samples were then treated
with RNase A (Sigma) and cleaned using QIAquick PCR purification
kit (Qiagen). Next, qPCR was carried out with HOT FIREPol
EvaGreen qPCR Mix Plus (no Rox, Solis BioDyne) and primers for
cyclin B3 (50 AAGACACTGACCTTGTCCCG 30 and 50 AGAGGGC-
CAGGAGTAAGGAG 30) and the loading controls: actin (50 GAAGTG
TGACGTGGACATCC 30 and 50 CTCGTCATACTCCTGCTTGC 30) and
TATA-binding protein (50 CACGAACCACGGCACTGATT 30 and 50
TTTTCTTGCTGCCAGTCTGGAC 30). The reaction was performed on
a PCR Stratagene MX3005P system. Fold change in expression over
control was calculated using the delta-delta Ct method (Livak &
Schmittgen, 2001).
Proliferation assay
One thousand cells per well were seeded and treated or not with
1 lg/ml of doxycycline, 3 lM of Asv and 500 lM of IAA for
1 week; then, cells were fixed and stained with a solution contain-
ing 0.05% crystal violet (Sigma-Aldrich), 1% formaldehyde (Sigma-
Aldrich), 1% methanol in PBS for 10 min.
FACS analysis
Cells were incubated with 10 lM of EdU for 1 h before being
harvested and fixed in 70% ethanol at 4°C overnight. Next, EdU
was labelled with the fluorophore Alexa 647 using Click-iT EdU
Imaging Kit (Invitrogen) and DNA were stained with 5 lg/ml of
propidium iodide (Fluka) and 150 lg/ml of RNAseA (Sigma-
Aldrich). FACS profiles were obtained from data acquired on Accuri
C6 Flow cytometer (BD Biosciences).
EdU pulse chase
Cells were incubated with or without the DIA cocktail for 4 h. After-
wards, 10 lM EdU was added for 1 h and washed 3–5× with PBS
before re-incubating in media with or without the DIA cocktail.
Starting at EdU washout, cells were harvested every 3 h for 12 h
and samples prepared and analysed as noted previously.
Cell synchronisation
To enrich mitotic cells and block cells in metaphase, we used a
single 24-h Thymidine block release. Apcin (25 lM) and proTAME
(6 lM) were added 12 h after the release for 2 h before fixation and
analysis. For more efficient mitotic enrichment to collect cells for
proteomic or immunoblotting analysis, we pre-synchronised cells by
serum starvation for 72 h, followed by a 24-h release into serum
and Thymidine containing medium, followed by release from
Thymidine. ProTAME (6 lM) was added 12 h after release for 2–
4 h and mitotic cells were collected by shake-off.
siRNA transfection
siRNAs were resuspended to 20 lM stock concentration. 1.5 ml
20 × 104 cells were reverse transfected with siRNA diluted in 500 ll
MEM (Gibco) media containing (10 ll) siRNA-MAX reagent (Invit-
rogen) and a final concentration of 80 nM siRNA. After 7 h-O/N
incubation, the media was changed to the standard growth media.
The cells were subsequently used for analysis after 48 h, or 72 h in
the case of CCNB3. The following siRNAs were used for this study
siGWL (Qiagen Ltd SI02653182 HsMASTL7 FlexiTube) and “on-
target plus” smart-pool siRNAs (Dharmacon/Horizon) for ARPP19,
ENSA, CCNB3, CCNB1, CCNB2, CCNA2, CCNA1, CDC27, B55a,
B55d. As a negative control, we used All Stars negative control
siRNA (Qiagen 1027280). In the case of Gwl and ENSA/ARPP siRNA
transfections, cells were synchronised 12 h after siRNA transfection
by a 25-h single Thymidine block and analysed 10–12 h after
release.
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Immunoblotting
Cells were pre-treated for 2 h with 1 lg/ml of doxycycline (Clon-
tech) and then 3 lM of asunaprevir (Asv; ApexBio) and/or 500 lM
IAA were added to the media for indicated time periods. Cells were
harvested and lysed in EBC buffer (50 mM Tris pH 7.5, 120 mM
NaCl, 0.5% NP-40, 1 mM EDTA, 1 mM DTT, protease and phos-
phatase inhibitors [Complete and PhosStop; Roche Diagnostics])
then mixed with 5× sample buffer (0.01% bromophenol blue,
62.5 mM Tris–HCl pH 6.8, 7% SDS, 20% sucrose and 5% b-mercap-
toethanol). The samples were sonicated then boiled at 95°C for
5 min. Samples were analysed by Western blotting and the signal
was detected using Immobilon Western Chemiluminescent HRP
substrate (Millipore). The intensity of cyclins A2 and B1 signals was
quantified using ImageJ software. GAPDH was used to normalise
the samples.
Immunofluorescence
Cells were fixed for 10 min with 3.7% formaldehyde (Sigma-
Aldrich) in PBS or with 100% ice-cold methanol for 1 min, washed
in PBS and permeabilised with PBS-containing 0.5% NP-40 for 10–
20 min. Following 30 min blocking in 3% bovine serum albumin
(BSA, Sigma-Aldrich), cells were labelled with the indicated anti-
bodies diluted in 3% BSA/PBS. Secondary antibodies were labelled
with Alexa Fluor dyes purchased from Invitrogen. Cell nuclei were
counterstained with 4,6-diamidino-2-phenylindole dihydrochloride
(DAPI; Sigma-Aldrich) then slides were mounted with ProLong
Diamond Antifade Mountant (Invitrogen), or if cells were grown in
96-well PerkinElmer CellCarrier Ultra polystyrene plates (Perki-
nElmer cat. no 6005550), they were left in 300 ll PBS at 4°C and
analysed within 1 week.
Cold treatment
Cells were grown on coverslips and were or not pre-treated with
1 lg/ml of doxycycline for 2 h; then, 3 lM of Asv and 500 lM of
IAA were added for 4 h. Next, the cells were incubated on ice for
10 min. For microtubule regrowth assay, the cells were re-incubated
at 37°C for indicated times. Fixation was carried out with PHEM
(60 mM Pipes, 25 mM HepesKOH pH 7.0, 5 mM EGTA, 4 mM
MgSO4, 0.5% NP-40 and 3.7% formaldehyde) for 5 min followed
by 95% ice-cold methanol/5 mM EGTA for 5 min. The samples
were then subjected to immunofluorescence, widefield microscopy
and deconvolution.
Chromosome spreads
Cells were synchronised by single Thymidine release and
proTAME/Apcin arrest as described above. Mitotic cells were
collected by shake-off and resuspended in warm 75 mM KCl
solution for 10 min before centrifugation. After aspirating KCl,
methanol: acetic acid (3:1) was added to cells and incubated at
RT for 5 min. Cells were centrifuged and resuspended in 300–
500 ll remaining solution and dropped on glass coverslips. They
were allowed to dry for 1 h prior to additional 4% Formalde-
hyde fixation for 10 min followed by immunofluorescence using
Ki67 antibodies.
Widefield live-cell microscopy
Cells were seeded on l-slides from Ibidi. Cells were pre-treated
with 2 lg/ml of doxycycline for 2 h before imaging, and 3 lM
of Asv and 500 lM of IAA were added at the beginning of the
imaging. To observe the nucleus, cells were pre-treated with
50 nM SiR-DNA (Spirochrome) for 2 h. To analyse mitotic entry,
time-lapse microscopy was performed in an environmental cham-
ber (Digital Pixels, Microscopy Systems & Solutions) heated at
37°C with 5% CO2 supply using an Olympus IX71 equipped with
Orca-flash4.0LT camera and a LUCPlanFLN, NA 0.45, 20× objec-
tive, or 0.64 NA, LUCPlanFLN 40× lens and 2 × 2 binning. Cells
were imaged using differential interference contrast (DIC), and
fluorescent illumination using a Lumencor Spectra LED light
source, and 640/40 excitation, 705/72 emission filters. Images
were acquired every 5 min using Micro-Manager v1.4 software
and cells that rounded-up and condensed their nucleus were
scored.
Widefield immunofluorescence microscopy and deconvolution
Slides were imaged using an Olympus IX70 equipped with
CoolSNAP HQ2 camera and an UApo N 340 NA 1.35, 40× oil
immersion objective controlled by Micro-Manager v1.4 software.
Stacks were taken at 0.2-lm intervals and deconvolved using
the Huygens classic maximum-likelihood estimation algorithm
(Scientific Volume Imaging) based on a measured point spread
function.
Airyscan confocal microscopy (Zeiss)
Confocal imaging was performed on the Airy scan module of Zeiss
LSM880 (Carl Zeiss AG, Germany) with Plan-Apochromat 63x/1.4
Oil objective in a live support chamber (Digital Pixels, Microscopy
Systems & Solutions) at 5% CO2 and 37°C. The “Fast” scanning
mode was used to speed up the imaging. At each imaging position,
seven axial slices with 2-lm interval were taken in three fluores-
cence channels including EGFP, RFP and Cy5. The excitation wave-
lengths were 488, 561 and 633 nm. The emission filters in front of
the Airyscan detectors were BP495-550, BP495-620 and LP645,
respectively. Each image was accumulated from four scans to mini-
mise laser-induced photo-bleaching and photo-toxicity. The time
lapses were set to last over 18 h with 5-min intervals. Raw images
were processed using Airyscan processing algorithm in Zen (Carl
Zeiss AG, Germany). The processed image sequence was then
maximum projected.
Spinning disc confocal imaging on operetta (PerkinElmer)
High-throughput imaging was performed on Operetta CLS (Perki-
nElmer Ltd@) in confocal mode with 40×/0.9 water objective.
Cells were cultured and imaged in PerkinElmer CellCarrier Ultra
96-well plates. At each imaging point, three axial slices with 4-
lm interval were scanned every 5 min in three fluorescence chan-
nels including EGFP, RFP and Cy5. The imaging lasted around
18 h in 5% CO2 and 37°C live environment. The image sequence
was maximum projected and then analysed using Harmony
software.
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Image segmentation and quantification of immunofluorescence
Regions of interest were either manually generated in ImageJ or
using Harmony segmentation algorithms. Mean and sum intensity
were estimated in ImageJ or Harmony and plotted using Python
Pandas, Matplotlib and Seaborn APIs (https://www.python.org,
https://matplotlib.org,https://seaborn.pydata.org).
High pH reverse-phase chromatography
and phospho-enrichment
Control and DIA-treated cells were lysed in 2% SDS in Dulbecco’s
PBS-containing protease and phosphatase inhibitors (Roche; mini-
cOmplete protease inhibitors EDTA-free, PhosStop). Lysates were
homogenised by sonication using a probe sonicator (Branson soni-
fier, 20% power, 30 s). Two hundred microgram protein was reduced
with 25 mM TCEP (Thermo Pierce), alkylated with N-ethylmaleimide
(Sigma, 55 mM prepared fresh) and then precipitated using the chlo-
roform–methanol method. The protein precipitate was resuspended
in 0.1 M triethylammonium bicarbonate (TEAB), pH 8.5 and digested
first with 2 lg LysC (Wako) for 4 h and then 2 lg trypsin (Thermo
Pierce) overnight. The digest was then reacted with 6-plex TMT
reagents (Thermo Pierce) using the manufacturer’s recommended
protocol. The TMT-labelled peptides were then mixed.
Peptides were separated off-line by high pH reverse-phase chro-
matography using an Ultimate 3000 high-performance/pressure
liquid chromatography system (HPLC; Thermo Dionex) equipped
with a BEH 4.6 cm × 150 mm BEH C18 column (Waters) using the
following mobile phases: (A) 10 mM ammonium formate, pH 9.3
and (B) 10 mM ammonium formate, pH 9.3 in 80% acetonitrile
(ACN). Peptides were eluted using a linear gradient into 24 frac-
tions. Five percent of each fraction was dried and retained aside for
total proteome analysis. The remaining 95% was taken forward for
phospho-enrichment.
Phospho-enrichment was performed using magnetic Ti:IMAC
beads according to the manufacturer’s instructions (Resyn Bios-
ciences), similar to previously described (Hiraga et al, 2017). Dried
fractions were resuspended in load buffer (80% ACN, 5% TFA, 5%
glycolic acid) and combined into 16 fractions in the following
manner: F17 + F1, F18 + F10, F19 + F11, F20 + F12, F21 + F14,
F23 + F15, F24 + F16. Enriched phosphopeptides were concentrated
by evaporation.
LC-MS/MS and MS data analysis
Peptides were resuspended in 5% formic acid and separated by
reverse-phase chromatography on a Ultimate3000 RSLCnano HPLC
(Thermo Dionex) equipped with an EasySpray 75 lm × 50 cm
column (Thermo Scientific). Peptides were eluted using a linear
elution gradient from 2 to 35% B over 2 h using the following mobile
phases: (A) 0.1% formic acid and (B) 80% ACN + 0.1% formic acid.
Peptides were then ionised and desolvated in an EasySpray electro-
spray source with a 2.5 kV voltage applied between the emitter and
the ion transfer capillary front-end of a Fusion Linear Ion Trap-Orbi-
trap mass spectrometer (Thermo Scientific). The acquisitions were
data-dependent. For MS1 scans, ions from 350 to 1,400 m/z were
selected using the quadrupole andm/z scanned using the Orbitrap at
120,000 resolution. For MS2 scans, the instrument was operated in
top speed mode. Precursors were selected using a 1.6 m/z window
for CID fragmentation at 30 normalised collision energy units
followed by m/z measurement in the linear ion trap. The top 3 MS2
fragments were then selected for synchronous precursor selection
(SPS) using an isolation window of 2 m/z and a maximum injection
time of 300 ms. The MS2 fragments were then subjected to further
HCD fragmentation at 55 normalised collision energy units. An MS3
scan of the HCD fragments was then performed in the Orbitrap at
60,000 resolution using a scan range of 100 to 150 m/z.
Peptide identification and quantitation were performed using
MaxQuant (version 1.5.6.5) (Cox & Mann, 2008), which incorporates
the Andromeda search engine (Cox et al, 2011). Default parameters
for TMT quantitation were used in MaxQuant, allowing for the
following variable modifications: phospho(STY), protein N-terminal
acetylation, glutamine to pyro(glutamate) conversion and deamida-
tion of Gln and Asn. The human reference proteome from UniProt
(accessed on 25 July 2016) was used as the sequence database for
the identification. Raw Data are available via ProteomeXchange with
identifier PXD012100. Post-MaxQuant processing was performed
using R (version 3.5.0). Potential contaminant proteins and hits to
the reverse database were removed from consideration. TMT
reporter was normalised by the median protein TMT reporter intensi-
ties to correct for unequal loading and also corrected for isotope
contamination. Phosphorylation site ratios were then calculated for
each of the three biological replicates and normalised to the ratios
measured for the total protein. Fold change cut-offs at x  1.96s was
determined by modelling log ratios as a normal distribution. Motif
analysis was performed by mapping regular expressions downloaded
for phosphorylation consensus motifs from ELM. This was
performed on a filtered dataset considering only those phosphoryla-
tion sites with a localisation probability above 0.75.
Functional classification of the candidates
Outliers were analysed for biological process ontology. Annotations
were extracted from the Gene Ontology database using QuickGO.
Only qualifier ECO:0000269 experimental evidence used in manual
assertion was considered. Biological process ontology verified by
direct assay or mutant phenotype from Uniprot database was used
to complement the protein classification.
Protein interaction map
The interactome was built from human protein–protein interaction
(PPI) databases. All outliers were considered to build a PPI map
using the software Cytoscape 3.5.1. Human PPIs from databases
were retrieved using the plugin Bisogenet. Small-scale studies were
considered and in vivo interactions or PPIs from direct complexes
were displayed. The PPI map was complemented using data
concerning protein complexes obtained from Uniprot and Corum
(http://mips.helmholtz-muenchen.de/corum/). Only PPIs relevant
or possibly related to mitosis and proteins present in several protein
complexes were shown.
Mathematical modelling of mitotic substrate phosphorylation
We have extended our previous model (Rata et al, 2018) with three
different (early, intermediate and late) mitotic substrates showing
20 of 23 The EMBO Journal 39: e104419 | 2020 ª 2020 The Authors
The EMBO Journal Nadia Hégarat
different sensitivities to cyclin:Cdk1 complexes and PP2A:B55 phos-
phatase (see Fig 9). CycB:Cdk1, but not CycA.Cdk1, is regulated by
inhibitory Cdk1-phosphorylation controlled by Wee1 and Cdc25.
Both of the Tyr-modifying enzymes are regulated by CycB:Cdk1
itself as well as by CycA:Cdk1 and PP2A:B55. The activity of PP2A:
B55 is controlled by the Greatwall-ENSA pathway which is activated
by cyclin:Cdk1-dependent phosphorylation of Greatwall kinase. The
early mitotic (prophase) substrates could be phosphorylated by both
cyclin:Cdk1 complexes and dephosphorylated by an unknown phos-
phatase. In contrast, the intermediate (prometaphase) and the late
mitotic substrates are both dephosphorylated by PP2A:B55. While
the intermediate substrates are phosphorylated by both cyclin:Cdk1
complexes, the phosphorylation of late substrates requires CycB:
Cdk1 activity. We used nonlinear ordinary differential equations to
describe the rate of change for protein concentrations in the
network.
All the reactions are described by law of mass action kinetics
except for the early mitotic substrates (pSearly), Wee1 and Cdc25
which are approximated by the Hill-kinetics. The rate constants are
abbreviated by “k” with subscripts referring to the type of reaction
(a-activation, i-inhibition, p-phosphorylation and dp-dephosphoryla-
tion) and the substrate of the reaction. The numerical values of
kinetic parameters are provided in the XPPAut “ode” code that
allows the users to reproduce Fig 9 (see Code in EV1).
Statistical analysis
All experiments included at least three independent biological
repeats. Sample size per repeat varied between experiments and is
indicated in the figure legends. Sample size was based on standard
practice in cell biological assays and not specifically pre-estimated.
P-values were calculated using an independent two-sample t-test.
Levels of significance are indicated by stars (*P < 0.05, **P < 0.01,
***P < 0.001). For all experiments, samples were not randomised
and the investigators were not blinded to the group allocation
during experiments and outcome assessment. No exclusion criteria
were used and all collected data were used for statistical analysis.
Data availability
Cell lines and reagents to establish endogenous double degron tags
are available upon request (contact HH at hh65@sussex.ac.uk). The
mass spectrometry data from this publication have been deposited
to the ProteomeXchange partner PRIDE database (https://www.eb
l.ac.uk/pride/) and assigned the identifier PXD012100 (http://
www.ebi.ac.uk/pride/archive/projects/PXD012100).
Expanded View for this article is available online.
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